Explore the evolving role of continuous glucose monitoring (CGM) in managing type 2 diabetes, with a focus on NICE NG28 guidance1. Host Adam Dawes and his guest Dr. Jackie Elliott discuss the criteria for CGM use, the transition from intermittently-scanned CGM to real-time CGM, and the comparison of NICE guidelines with international standards

With / speaker;

Dr. Jackie Elliot is a Clinical Lead for Diabetes, Senior Clinical Lecturer, and Honorary Consultant at Sheffield Teaching Hospitals NHS Foundation Trust.

*If your glucose alerts and readings from Dexcom CGM System do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Jackie Elliot Study

Elliott J. et al. Clinical outcomes of a real-world prospective study using Dexcom ONE continuous glucose monitoring in people with diabetes treated with two or more insulin injections per day. Diabet Med. 2025.e15519.

NICE. Type 2 diabetes in adults: management. Accessed March, 2025.

https://www.nice.org.uk/guidance/ng28

† © NICE [2023]. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Other guidance mentioned.

ADA. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes. Diabetes Care. 2025;48:S14–S26

SIGN. Optimising glycaemic control in people with type 1 diabetes. Accessed March 2025. http:// www.sign.ac.uk/ our-guidelines/optimising-glycaemic-control-in-people-with-type-1-diabetes/

Davies MJ, et al. Consensus report on management of hyperglyceamia in T2D. Diabetologia. 2022;65: 1925–1966

MAT-7899

This podcast has been created and fully funded by Dexcom UK & Ireland and intended for healthcare professionals practising in the United Kingdom & Ireland.
Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice.

All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom User Guide . For product-related questions, please refer to the instructions for use. For complete safety information, go to https://www.dexcom.com/en-gb/safety-information . Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. © 2025 Dexcom, Inc. All rights reserved. Dexcom Distribution Ltd, www.dexcom.com.
Further CPD accredited education can be found on the Dexcom Education Hub